Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug
- Details
- Category: Pfizer
![Pfizer Pfizer](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
AstraZeneca launches and prices a EUR750 million debut eurobond
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](http://www.worldpharmanews.com/images/stories/logo/astrazeneca_b.gif)
Study Results for Aclidinium Bromide, a Novel Anticholinergic
- Details
- Category: Clinical Trials
![Forest Laboratories Forest Laboratories](http://www.worldpharmanews.com/images/stories/logo/forest.gif)
Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds
- Details
- Category: Takeda
![Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited](http://www.worldpharmanews.com/images/stories/logo/takeda.gif)
ERS COPD Research Awards 2007 Sponsored by Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](http://www.worldpharmanews.com/images/stories/logo/boehringeringelheim.gif)
Invega® receives marketing authorisation in European Union for treatment of schizophrenia
- Details
- Category: Product
![Janssen-Cilag Janssen-Cilag](http://www.worldpharmanews.com/images/stories/logo/janssen-cilag.gif)
Novartis completes agreement with Bayer Schering related to Betaseron®
- Details
- Category: Novartis
![Novartis AG Novartis AG](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
More Pharma News ...
- FDA Accepts NDA Filing for Cleviprex(TM) for the Treatment of Acute Hypertension
- Merck & Co., Inc. Announces Completion of NovaCardia, Inc. Acquisition
- FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
- Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits
- Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib
- ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- PLIVA Enters Oncology Business in Germany